Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Single-site, Double-blind, Placebo-controlled, Randomized Clinical Trial with an Open-label Extension Phase to Examine the Safety, Efficacy, Durability, Subjective Experiences, Acute Effects, and Suitability of Psilocybin Combined with Psychological Support (Psi-PS) for Military Veterans and First Responders with Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD)

Next Previous
Trial Profile

A Phase 2 Single-site, Double-blind, Placebo-controlled, Randomized Clinical Trial with an Open-label Extension Phase to Examine the Safety, Efficacy, Durability, Subjective Experiences, Acute Effects, and Suitability of Psilocybin Combined with Psychological Support (Psi-PS) for Military Veterans and First Responders with Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD)

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Psilocybin (Primary) ; Maltodextrin
  • Indications Alcoholism; Post-traumatic stress disorders
  • Focus Adverse reactions
  • Acronyms Psi-PS; Psi-PS

Most Recent Events

  • 07 Jul 2025 According to Filament Health Corp media release, the U.S. Food and Drug Administration (FDA) has authorized a phase 2 clinical trial of PEX010, for the treatment of alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD) in military veterans and first responders.
  • 06 Mar 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top